Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its ...

Spirit Airlines (SAVE) extends its debt refinancing deadline with the US Bank National Association, sending the stock soaring ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Led by Sen. Dick Durbin of Illinois, senators question if direct-to-consumer website telehealth deals are a new way around ...